参考文献

1. Heymann W，Hackel DB，Harwood S，et al.Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med，1959，100 （4）：660-664.
2. Kerjaschki D，Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border.Proc Natl Acad Sci U S A，1982，79（18）：5557-5561.
3. Debiec H，Guigonis V，Mougenot B，et al.Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med，2002，346（26）：2053-2060.
4. Beck LH Jr，Bonegio RG，Lambeau G，et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.N Engl J Med，2009，361（1）：11-21.
5. Ronco P，Debiec H.Target antigens and nephritogenic antibodies in membranous nephropathy：of rats and men.Semin Immunopathol，2007，29（4）：445-458.
6. Ronco P，Debiec H.Advances in membranous nephropathy：success stories of a long journey.Clin Exp Pharmacol Physiol，2011，38（7）：460-466.
7. Nirula A，Glaser SM，Kalled SL et al.What is IgG4？A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol，2011，23（1）：119-124.
8. Hofstra JM，Debiec H，Short CD，et al.Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.J Am Soc Nephrol，2012，23（10）：1735-1743.
9. Hoxha E，Harendza S，Zahner G，et al.An immunofluorescence test for phospholipase-A（2）-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.Nephrol Dial Transplant，2011，26（8）：2526-2532.
10. Cybulsky AV，Quigg RJ，Salant DJ.Experimental membranous nephropathy redux.Am J Physiol Renal Physiol，2005，289（4）：F660-671.
11. Glassock RJ.The pathogenesis of idiopathic membranous nephropathy：a new paradigm in evolution.Contrib Nephrol，2013，181：131-142.
12. Prunotto M，Carnevali ML，Candiano G，et al.Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.J Am Soc Nephrol，2010，21（3）：507-519.
13. Bruschi M，Carnevali ML，Murtas C，et al.Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis：Alfa-enolase and borderline antigens. J Proteomics，2011，74（10）：2008-2017.
14. Nangaku M，Shankland SJ，Couser WG.Cellular response to injury in membranous nephropathy.J Am Soc Nephrol，2005，16（5）：1195-1204.
15. Johnson R，Yamabe H，Chen YP，et al.Glomerular epithelial cells secrete a glomerular basement membrane-degrading metalloproteinase. J Am Soc Nephrol，1992，2 （9）：1388-1397.
16. Pippin JW，Durvasula R，Petermann A，et al.DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes.J Clin Invest，2003，111（6）：877-885.
17. Shankland SJ.Podocyte’s response to injury：role in proteinuria and glomerulosclerosis. Kidney Int，2006，69 （12）：2131-2147.
18. Polanco N，Gutierrez E，Covarsi A，et al.Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.J Am Soc Nephrol，2010，21：697-704.
19. Pei Y，Cattran D，Greenwood C.Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis.Kidney Int，1992，42：960-966.
20. Cattran D. Management of membranous nephropathy：when and what for treatment.J Am Soc Nephrol，2005，16：1188-1194.
21. Lai KN.Membranous nephropathy：when and how to treat. Kidney Int，2007，71（9）：841-843.
22. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO clinical practice guideline for glomerulonephritis.Kidney Int Suppl，2012，2：139-274.
23. Schieppati A，Perna A，Zamora J，et al.Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.Cochrane Database Syst Rev，2004，（4）：CD00429.
24. Hofstra JM，Branten AJ，Wirtz JJ，et al.Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy：a randomized controlled trial.Nephrol Dial Transplant，2010，25：129-136.
25. Cattran DC，Alexopoulos E，Heering P，et al.Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome：workshop recommendations. Kidney Int，2007，72（12）：1429-1447.
26. Alexopoulos E，Papagianni A，Tsamelashvili M，et al.Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant，2006，21（11）：3127-3132.
27. Praga M，Barrio V，Juárez GF，et al.Tacrolimus monotherapy in membranous nephropathy：a randomized controlled trial.Kidney Int，2007，71：924-930.
28. Chen M，Li H，Li XY，et al.Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy：a multicenter randomized controlled trial.Am J Med Sci，2010，339：233-238.
29. Cattran DC，Appel GB，Hebert LA et al.Cyclosporine in patients with steroid-resistant membranous nephropathy：a randomized trial.Kidney Int，2001，59：1484-1490.
30. Chan TM，Lin AW，Tang SC，et al.Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.Nephrology（Carlton），2007，12：576-581.
31. Dussol B，Morange S，Burtey S，et al.Mycophenolate mofetil monotherapy in membranous nephropathy：a 1-year randomized controlled trial.Am J Kidney Dis，2008，52：699-705.
32. Ruggenenti P，Chiurchiu C，Brusegan V，et al.Rituximab in idiopathic membranous nephropathy：a one-year prospective study.J Am Soc Nephrol，2003，14：1851-1857.
33. duBuf-Vereijken PW，Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant，2004，19：2036-2043.
34. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome：a clinical conundrum. J Am Soc Nephrol，2007，18：2221-2225.
上一章目录下一章